Loading clinical trials...
Loading clinical trials...
NeoTISLEGA - A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
Conditions
Interventions
Tislelizumab
FLOT Chemotherapy
Locations
4
Germany
Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF)
Frankfurt, Germany
Hämatologisch-Onkologische Praxis Eppendorf (hope)
Hamburg, Germany
Universitätsklinikum Leipzig
Leipzig, Germany
Klinikum rechts der Isar München der TU München
München, Germany
Start Date
December 12, 2025
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
December 19, 2025
NCT06340711
NCT06078709
NCT04389632
NCT05745857
NCT04939051
NCT06901531
Lead Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions